ArticleCureus2026
Utilization of Imaging in the Diagnosis and Surveillance of Pancreatic Ductal Adenocarcinoma (PDAC): Analysis of the TRICARE Data.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background It is unclear if adding MRI in the pre-treatment staging for pancreatic ductal adenocarcinoma (PDAC) is associated with changes in treatment compared to only obtaining a CT scan of the abdomen/pelvis. Similarly, there remains unclear benefit from frequent postoperative surveillance imaging after surgical resection for PDAC. Methodology Claims data from the Military Health Services Data Repository were used to identify all adult patients with PDAC who underwent surgical resection between 2017 and 2022. Patient demographics, medical and surgical interventions, radiographic studies, and survival data were sourced from the TRICARE database. The proportion of patients undergoing neoadjuvant chemotherapy compared to upfront surgical resection was compared between patients with and without a preoperative abdominal MRI, along with those who underwent one versus multiple preoperative CTs, after controlling for covariates of interest. Overall survival was compared between patients who underwent surveillance imaging every six months versus those with more frequent imaging. Results There was no significant difference in whether patients who had preoperative MRIs underwent surgery first (88.5% vs. 77.9%, p = 0.58). However, among patients who received multiple CT scans, there was a higher proportion who underwent surgical resection before chemotherapy (92.2% vs. 74.3%, p = 0.017). Decreased surveillance intervals were associated with a decreased hazard ratio (0.88, p = 0.007) when compared to the six-month standard surveillance frequency, although only after the 24-month mark. Conclusions Overall, preoperative MRIs were not associated with initial choice of treatment (i.e., surgery first or chemotherapy first). Frequency of surveillance imaging might differ before and after the 24-month mark, but disentangling the reason for imaging in the post-surgical surveillance period is difficult and introduces bias.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.